Rapid and Sustained Eyelid Elevation in Acquired Blepharoptosis with Oxymetazoline 0.1%: Randomized Phase 3 Trial Results
Jason Bacharach,1 David L Wirta,2 Robert Smyth-Medina,3 Michael S Korenfeld,4 Shane R Kannarr,5 Shane Foster,6 Mark J Jaros,7 Charles B Slonim8 1North Bay Eye Associates, Petaluma, CA, USA; 2Aesthetic Eye Care Institute & Eye Research Foundation, Newport Beach, CA, USA; 3North Valley Eye Medical...
Main Authors: | Bacharach J, Wirta DL, Smyth-Medina R, Korenfeld MS, Kannarr SR, Foster S, Jaros MJ, Slonim CB |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-06-01
|
Series: | Clinical Ophthalmology |
Subjects: | |
Online Access: | https://www.dovepress.com/rapid-and-sustained-eyelid-elevation-in-acquired-blepharoptosis-with-o-peer-reviewed-fulltext-article-OPTH |
Similar Items
-
Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials
by: Wirta DL, et al.
Published: (2021-10-01) -
Difference in vasoconstrictors: oxymetazoline vs. brimonidine
by: Nwanneka Okwundu, et al.
Published: (2021-02-01) -
An Alternative Algorithm for Müller Muscle Conjunctival Resection Surgery for Blepharoptosis Management
by: Gamze Ozturk Karabulut, et al.
Published: (2019-12-01) -
The myostatin null mutation and clenbuterol administration elicit additive effects in mice
by: A.C. Dilger, et al.
Published: (2010-01-01) -
An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder
by: Frankel J, et al.
Published: (2022-03-01)